Patient Views on a Pre-treatment Blood Test to Predict Outcomes Following PD-1 Inhibitor Therapy: A Qualitative Study

Area of Science:

• Oncology
• Immunotherapy
• Patient-Reported Outcomes

Background:

• Anti-PD-1 immunotherapy offers benefits for advanced melanoma but has limited efficacy in less than half of patients.
• Severe adverse effects associated with anti-PD-1 therapy necessitate the development of predictive biomarkers.
• Predictive biomarker tests aim to identify patients likely to respond to immunotherapy, improving treatment selection.

Purpose of the Study:

• To qualitatively explore advanced melanoma patients' perspectives on the value of predictive biomarker tests for anti-PD-1 immunotherapy.
• To understand how such tests would influence patients' treatment decision-making processes.

Main Methods:

• Semi-structured interviews were conducted with 14 melanoma patients starting PD-1 inhibitor therapy.
• Participants were presented with a hypothetical blood-based biomarker test scenario predicting immunotherapy success or failure.

Main Results:

• Patients perceive significant value in predictive tests, regardless of outcome, for managing expectations and aiding decisions.
• Test results directly influence patients' willingness to undergo PD-1 inhibitor therapy.
• Ultimately, patients rely on their treating doctor's interpretation of test results and guidance for treatment decisions.

Conclusions:

• Advanced melanoma patients recognize the value of predictive tests for anti-PD-1 immunotherapy.
• Effective communication of test results should include discussions on alternative treatments and doctor's recommendations.
• Integrating patient perspectives is crucial for developing and implementing biomarker-based predictive tests.